Brand Intelligence Graphcompany
Company Overview
About Merck & Co.
Merck & Co. is one of the world's largest research-driven pharmaceutical companies, founded in the United States in 1891 as a subsidiary of the German Merck KGaA and now an independent American company headquartered in Rahway, New Jersey, trading on NYSE (MRK). The company generated approximately $63.6 billion in revenues for FY2024 under CEO Robert Davis, anchored by Keytruda (pembrolizumab)—the world's best-selling cancer drug—which generated approximately $25 billion in global sales as the dominant checkpoint inhibitor immunotherapy across over 40 approved tumor indications including lung cancer, melanoma, bladder cancer, cervical cancer, and dozens more. Merck's animal health subsidiary, Merck Animal Health, is a global leader in livestock and companion animal medicines including Bravecto (flea/tick prevention) and contributes approximately $6 billion in revenues.
Business Model & Competitive Advantage
Keytruda's dominance in oncology immunotherapy is the defining financial fact of modern Merck: its combination use with chemotherapy as the standard first-line treatment for many cancers creates treatment pathways that benefit Merck when any of 40+ FDA-approved indications is diagnosed. The Bristol-Myers Squibb PD-1/PD-L1 checkpoint inhibitor (Opdivo) competes directly across many of the same tumor types, while AstraZeneca's Imfinzi, Pfizer/Merck's partnership on Bavencio, and Roche's Tecentriq represent alternative checkpoint blockade options. Merck's Gardasil HPV vaccine franchise—historically a $7-8 billion annual revenue contributor—experienced a sudden revenue collapse in China in 2024 as the Chinese government shifted policy away from recommending foreign HPV vaccines, eliminating approximately $2 billion in annual China revenue.
Competitive Landscape 2025–2026
In 2025-2026, Merck's most critical strategic challenge is the Keytruda patent expiration approaching in 2028-2030, which threatens $25+ billion in annual revenues. Merck's pipeline response includes subcutaneous Keytruda formulations (extending patent protection for formulation), Winrevair (sotatercept) for pulmonary arterial hypertension approved in 2024 targeting $4+ billion in peak sales, islatravir for HIV (partnership with Gilead), and multiple oncology combinations. The 2024 acquisition of Prometheus Biosciences for $10.8 billion adds TL1A inhibitor pipeline for inflammatory bowel disease. Merck's $15+ billion annual R&D budget and business development activities are entirely focused on filling the post-Keytruda revenue gap through 2030.
The Merck & Co. Story
Founders
Recent Activity
View all →Company Timeline
Major milestones in Merck & Co.'s journey
Leadership Team
Meet the leaders behind Merck & Co.
Robert M. Davis
Robert M. Davis became CEO and a member of the board of directors on July 1, 2021, and was elected Chairman of the Board on December 1, 2022. At 58 years old with 11 years of tenure at Merck, Davis joined the company as Chief Financial Officer in 2014 with additional responsibility for real estate operations, corporate strategy, and business development. In 2016, his role expanded to include information technology and procurement, forming Global Services. Prior to becoming CEO, Davis served as President with responsibility for operating divisions including Human Health, Animal Health, Manufacturing, and Merck Research Laboratories. Under his leadership, Merck reported 2024 revenue growth of 10% excluding foreign exchange and delivered above-target performance with 114% Company Scorecard payout. Davis has orchestrated major acquisitions totaling over $35 billion including Verona Pharma ($10B, 2025), Prometheus Biosciences ($10.8B, 2023), and Acceleron ($11B, 2021) to diversify Merck's pipeline beyond Keytruda.
Richard R. DeLuca, Jr.
Richard R. DeLuca, Jr. serves as Executive Vice President and President of Merck Animal Health, overseeing the company's veterinary pharmaceutical and vaccine business. He leads strategy, operations, and commercial activities for this business segment which was spun off as a separate entity but maintains strategic ties to the parent pharmaceutical company.
Cristal N. Downing
Cristal N. Downing serves as Executive Vice President and Chief Communications & Public Affairs Officer, leading Merck's global communications strategy, corporate reputation management, government affairs, and stakeholder engagement. Her role encompasses internal communications, external media relations, crisis management, and advocacy initiatives that support the company's mission and strategic objectives.
Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li serves as Executive Vice President and President of Merck Research Laboratories (MRL), overseeing the company's global research and development organization. He leads scientific strategy, drug discovery, clinical development, regulatory affairs, and translational medicine efforts across Merck's portfolio spanning oncology, vaccines, cardiovascular disease, metabolic disorders, and infectious diseases. Under his leadership, MRL has advanced a pipeline of 20+ programs predicted to generate over $35 billion in sales by the middle of the next decade.
Key Differentiators
Market Leader
Merck & Co. is recognized as a market leader in the Healthcare Tech sector, demonstrating strong industry presence and customer trust.
Enterprise Scale
With $63.6B in revenue, Merck & Co. operates at enterprise scale with proven market validation.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Idexx Laboratories
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headqu
GE HealthCare
GE HealthCare Technologies Inc. is a Chicago, Illinois-based medical technology and digital health company — publicly traded on the NASDAQ (NASDAQ: GEHC) as an S&P 500 Health Care component — designin
Incyte
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation,
Biogen
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and com
Danaher Corporation
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, man
Revvity
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provid
Compare Merck & Co. with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Merck & Co.? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Merck & Co. Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Merck & Co. vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →